Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
LDP Panel Chief Calls for Earlier CGP Coverage in Cancer Care
Japan should expand insurance coverage for comprehensive genomic profiling (CGP) testing so that cancer patients can undergo the tests from the early stages of treatment, ruling Liberal Democratic Party lawmaker Tamayo Marukawa told Jiho. Marukawa, chair of the LDP’s Special…
To read the full story
Related Article
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- Few Testing Facilities, Timing of Coverage Pose Challenge in CGP Testing in Japan: Oncologist
February 27, 2025
- Oncologist Sees Need to Seek Middle Ground towards CGP Testing for 1st Line Therapy
February 17, 2025
- Trade Groups, Academic Societies Urge Govt to Expand Coverage for CGP Testing
December 26, 2023
- PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
July 4, 2023
- CGP Assays Prior to Initial Treatment Would Have Little Impact on Health Finances: Professor
May 31, 2023
- MHLW Panel OKs Research Report That Could Set Stage for Gene Profiling Before 1st-Line Cancer Therapy
March 15, 2023
REGULATORY
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Japan Finalizes Medical Data Sharing Blueprint, Eyes 2027 Bill
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…